Over a month ago |
Hot Stocks
|
Erasca announced dosing… Erasca announced dosing of the first patient in the HERKULES-1 Phase 1b trial evaluating ERK1/2 inhibitor ERAS-007 in combination with SHP2 inhibitor ERAS-601 in patients with RAS/MAPK pathway-altered solid tumors. "We are pleased with our team's efficient execution that resulted in dosing the first patient in our MAPKlamp trial in 2022 ahead of schedule," said Jonathan E. Lim, M.D., Erasca's chairman, CEO, and co-founder. "ERK and SHP2 inhibition with ERAS-007 and ERAS-601 targets critical downstream and upstream nodes in the RAS/MAPK pathway, offering a rational approach that is supported by early clinical data that we presented at our R&D Day in September. Notably, we reported four responses in nine patients with BRAF-driven tumors to either monotherapy ERAS-007 or ERAS-601. Three of these responses were in tumors with BRAF Class 2 or 3 alterations, including a confirmed response to monotherapy SHP2 inhibition in a patient with a BRAF Class 3 alteration, which is dependent on upstream receptor tyrosine kinase activation. We look forward to exploring the potential to address the high unmet need in these BRAF subtypes, which have no approved targeted therapies and represent up to 25% of all BRAF-driven tumors." ShowHide Related Items >><< - 12/13/22
- Erasca announces FDA clearance of IND application for ERAS-3490
- 12/09/22
- Erasca announces pricing of underwritten offering of common stock
- 12/09/22
- Erasca, Novartis enter worldwide license agreement for naporafenib
- 11/30/22
- Erasca announces CTCSA with Pierre Fabre to evaluate ERAS-007
- 01/03/22 Guggenheim
- Erasca price target lowered to $20 from $25 at Guggenheim
- 11/09/22
- Erasca reports Q3 EPS (29c), consensus (31c)
|
Hot Stocks
|
Erasca announced the… Erasca announced the United States Food and Drug Administration, FDA, has cleared an investigational new drug, IND, application for ERAS-3490, an orally available small molecule KRAS G12C inhibitor designed to have high central nervous system, CNS, penetration for the treatment of KRAS G12C-mutated solid tumors, including non-small cell lung cancer, NSCLC. "KRAS G12C is a prevalent oncogenic mutation that was historically considered undruggable. While first generation inhibitors have made great progress against this mutation, we believe that they do not sufficiently penetrate the blood-brain barrier which can lead to poor disease control, particularly in NSCLC, where up to 40% of patients may develop CNS metastases," said Jonathan E. Lim, M.D., Erasca's chairman, CEO, and co-founder. "ERAS-3490, our first homegrown development candidate, was selected for its robust CNS and systemic activity. We are pleased the FDA has cleared our IND for ERAS-3490." ShowHide Related Items >><< - 12/09/22
- Erasca announces pricing of underwritten offering of common stock
- 12/09/22
- Erasca, Novartis enter worldwide license agreement for naporafenib
- 11/30/22
- Erasca announces CTCSA with Pierre Fabre to evaluate ERAS-007
- 10/20/22
- Erasca announces CTCSA with Pfizer to evaluate ERAS-007
- 01/03/22 Guggenheim
- Erasca price target lowered to $20 from $25 at Guggenheim
- 11/09/22
- Erasca reports Q3 EPS (29c), consensus (31c)
|
On The Fly
|
Get caught up quickly on… ShowHide Related Items >><< - 12/06/22
- Walmart to pay $500,000 over workers' compensation prescription procedures
- 12/01/22
- Digimarc expands partnership with Walmart
- 11/29/22
- Upexi's toy brand Tytan Tiles to launch in Walmart retail stores in January
- 11/23/22
- Walmart 'shocked' at 'tragic' event at Chesapeake, Virginia store
- 11/08/22
- VMware, Equinix announce expanded global relationship
- 11/08/22
- HP Enterprise, VMware announce next phase of partnership
- 11/08/22
- Wipro, VMware extend collaboration with dedicated business unit
- 10/17/22
- VMware, First Nations University of Canada launch digital partnership
- 11/17/22
- General Motors, Vale sign long-term nickel supply agreement
- 08/15/22
- Vale fined BRL86.3M in Brazil over Brumadinho dam disclosures
- 07/28/22
- Vale reports Q2 iron ore production up 17% to 74.1 Mt
- 07/19/22
- Vale updates FY22 iron ore and copper production estimates
- 12/06/22
- Vietnam-based EV maker VinFast plans for U.S. IPO
- 12/02/22
- Ford reports November U.S. sales down 7.8% to 146,364 vehicles
- 11/28/22
- Musk says Apple 'threatened to withhold Twitter' from App Store
- 12/08/22
- RH says Q3 gross margin contracted 50bps
- 12/08/22
- RH to acquire Dmitriy & Co
- 12/08/22
- RH CEO to exercise expiring options
- 11/14/22
- Berkshire Hathaway adds TSMC, exits STORE Capital in Q3
- 12/08/22
- Paysafe announces reverse stock split
- 11/29/22
- Paysafe enters new partnership with Virgin Voyages
- 11/15/22
- Paysafe launches paysafecard as alternative payment on Microsoft.com, Xbox.com
- 10/19/22
- Paysafe announces new integrated payments partnership with HotelKey
- 11/02/22
- New York Times sees Q4 subscription revenues up 17%-20%
- 08/11/22
- New York Times jumps after ValueAct discloses 6.7% active stake
- 08/03/22
- New York Times sees FY22 CapEx approximately $55M
- 07/14/22
- Hasbro, New York Times to launch new Wordle board game
- 12/06/22
- Netflix CEO Sarandos sees multiple ad tiers over time
- 12/01/22
- Enthusiast Gaming, Netflix enter content partnership for Geeked: Toon-in
- 11/14/22
- Appaloosa exits positions in Kohl's, Occidental Petroleum, Micron
- 11/07/22
- Netflix to adapt video game 'Gears of War' into feature film, animated series
- 11/25/22
- Manchester United rises 16.8%
- 11/25/22
- Manchester United rises 9.9%
- 11/25/22
- Manchester United rises 8.6%
- 11/23/22
- Manchester United rises 17.7%
- $326.63 /
-48.88 (-13.02%) - 12/08/22
- Lululemon falls 9% to $340.75 after Q3 results and guidance
- 12/08/22
- Lululemon reports Q3 SSS up 22% or 25% on constant FX basis
- 10/05/22
- Xponential Fitness debuts workouts on Lululemon Studio
- 09/30/22
- Peloton, Lululemon reach settlement over athletic wear
- $21.10 /
-2.995 (-12.43%) - 12/01/22
- Li Auto delivers 15,034 vehicles in November, up 11.5%
- 11/01/22
- Li Auto delivers 10,052 vehicles in October, up 31.4%
- 10/01/22
- Li Auto delivers 11,531 vehicles in September, up 62.5% year-over-year
JAZZ Jazz Pharmaceuticals - $151.94 /
+1.715 (+1.14%) - 11/29/22
- Zymeworks says Hart-Scott-Rodino wait expires for Zanidatamab deal with Jazz
- 11/28/22
- Jazz to present six presentations on advancements in epilepsy outcomes
- 11/18/22
- Avadel says Delaware Court ordered Jazz to delist REMS Patent from Orange Book
- 11/18/22
- Jazz announces FDA approval of sBLA for Rylaze dosing schedule
- 12/09/22
- UAW says GM Ultium venture workers voted to join union
- 12/09/22
- Mullen Automotive hires Dixon as General Manager of Government Sales
- 12/07/22
- Interest rates, slow economy weigh on U.S. auto dealers, Cox Automotive says
- 12/05/22
- GM's BrightDrop adds DHL Express Canada to customer portfolio
- 12/09/22
- Apple, Ericsson sign global patent license agreement
- 12/07/22
- Aeris to acquire IoT business from Ericsson, terms not disclosed
- 12/07/22
- Ericsson, Aeris sign pact for Accelerator and Connected Vehicle Cloud businesses
- 11/03/22
- Ericsson's Vonage to pay customers $100M in FTC court order
- 12/09/22
- Erasca announces pricing of underwritten offering of common stock
- 12/09/22
- Erasca, Novartis enter worldwide license agreement for naporafenib
- 11/30/22
- Erasca announces CTCSA with Pierre Fabre to evaluate ERAS-007
- 10/20/22
- Erasca announces CTCSA with Pfizer to evaluate ERAS-007
- 12/08/22
- DocuSign jumps 14% to $49.80 after Q3 results beat estimates
- 12/08/22
- DocuSign reports Q3 adjusted gross margin 83% vs. 82% last year
- 10/04/22
- Cathie Wood says moved out of DocuSign, did not understand competition
- 09/28/22
- DocuSign announces restructuring plan, to reduce workforce by 9%
- $483.08 /
+1.755 (+0.36%) - 11/30/22
- Costco November total SSS ex gas and FX rose 5.3%
- 11/30/22
- Costco reports November revenue $19.17B, Q1 SSS up 6.6%
- 11/15/22
- Large retailers, discount stores, Amazon jump on Q3 earnings beat by Walmart
- 11/02/22
- Costco reports October comparable sales up 6.0%
- $309.44 /
-10.41 (-3.25%) - 08/09/22
- Cooper Companies appoints Nicholas Khadder general counsel
- 12/02/22
- Coinbase says Apple blocked last app release on NFTs
- 11/30/22
- Coinbase Wallet to stop supporting BCH, ETC, XLM, XRP
- 11/21/22
- Crypto names down in pre-market as bitcoin falls to one-week low
- 11/16/22
- Cathie Wood's ARK Investment bought 245.6K shares of Coinbase today
- 10/27/22
- Comtech awarded over $50M of incremental funding by U.S. Military
- 10/03/22
- Comtech awarded a contract by Tier-1 MNO for over $30M+
- 09/21/22
- Comtech awarded FMS contract for Ukrainian Government, no terms
- 09/15/22
- Comtech awarded London Police Service next generation 9-1-1 contract
- 12/08/22
- Chewy says now expects FY22 capex to come in slightly below 2.5% of sales
- 10/20/22
- Chewy expands CarePlus with new plan by Lemonade Pet
- 08/31/22
- Chewy falls -7.3%
- 08/30/22
- Chewy sees FY22 adjusted EBITDA margin 1.75%-2%
- 11/14/22
- Beyond Meat and American Cancer Society sign multi-year research agreement
- 11/09/22
- Beyond Meat sees Q4 operating expenses mid-$60M range
- 11/07/22
- Beyond Meat expands chicken portfolio with Chicken Nuggets, Popcorn Chicken
- 10/24/22
- Beyond Meat debuts Beyond Steak
- $544.94 /
+14.235 (+2.68%) - 12/08/22
- Broadcom reports Q4 cash from operations $4.583B, free cash flow $4.461M
- 12/08/22
- Broadcom raises quarterly dividend 12% to $4.60 per share
- 10/25/22
- Broadcom's Rally Software receives FedRAMP authorization
- 10/18/22
- Broadcom showcases hyperscale solutions at 2022 OCP Global Summit
- 12/09/22
- Arcellx trading resumes
- 12/09/22
- Arcellx reports results from CART-ddBCMA Phase 1 expansion trial
- 12/09/22
- Arcellx, Kite collaborate to develop CART-ddBCMA
- 12/09/22
- Arcellx trading halted, news pending
- 12/09/22
- Apple says employees have 'right to speak freely' about workplace conditions
- 12/07/22
- Apple introduces three new advanced data security features
- 12/06/22
- Apple updates App Store pricing, offers 700 new price points
- 12/09/22 BofA
- DocuSign price target lowered to $65 from $80 at BofA
- 12/09/22 Piper Sandler
- DocuSign upgraded to Neutral from Underweight at Piper Sandler
- 12/06/22 Citi
- DocuSign price target lowered to $59 from $76 at Citi
- 12/05/22 UBS
- DocuSign price target lowered to $52 from $65 at UBS
- $544.94 /
+14.235 (+2.68%) - 12/09/22 Truist
- Broadcom price target raised to $662 from $630 at Truist
- 12/09/22 BofA
- Broadcom price target raised to $650 from $625 at BofA
- 12/09/22 Wells Fargo
- Broadcom resumed with an Equal Weight at Wells Fargo
- 12/09/22 Cowen
- Broadcom price target raised to $555 from $540 at Cowen
- $326.63 /
-48.88 (-13.02%) - 12/09/22 Morgan Stanley
- Lululemon price target raised to $387 from $343 at Morgan Stanley
- 12/09/22 Jefferies
- Jefferies says 'sell shares now' with Lululemon Q3 'as good as it gets'
- 12/09/22 Wells Fargo
- Lululemon price target raised to $360 from $345 at Wells Fargo
- 12/09/22 Goldman Sachs
- Lululemon removed from Conviction Buy list at Goldman on tough comps
- 12/08/22 Societe Generale
- Ericsson price target raised to SEK 64 from SEK 55 at Societe Generale
- 11/09/22 Deutsche Bank
- Ericsson price target lowered to SEK 70 from SEK 80 at Deutsche Bank
- 11/08/22 Morgan Stanley
- Ericsson initiated with an Equal Weight at Morgan Stanley
- 11/01/22 JPMorgan
- Ericsson price target lowered to SEK 101 from SEK 125 at JPMorgan
- 12/09/22 Morgan Stanley
- RH price target lowered to $300 from $325 at Morgan Stanley
- 12/09/22 Jefferies
- RH price target lowered to $322 from $375 at Jefferies
- 12/09/22 Baird
- RH price target raised to $300 from $275 at Baird
- 11/21/22 Barclays
- RH downgraded to Equal Weight from Overweight at Barclays
- 12/07/22 Morgan Stanley
- Morgan Stanley 'incrementally more conservative' on Apple's December quarter
- 12/06/22 UBS
- Apple iPhone 14 Pro/Pro Max delivery times finally easing, says UBS
- 12/05/22 Wedbush
- Apple shift out of China will not be easy, says Wedbush
- 12/02/22 Morgan Stanley
- Morgan Stanley sees December quarter App Store forecast as 'conservative'
- 12/09/22 Cowen
- Netflix price target raised to $405 at Cowen, named a 'Best Idea for 2023'
- 12/09/22 Wells Fargo
- Wells Fargo upgrades Netflix shares on 'more ways to win' in 2023
- 12/09/22 Wells Fargo
- Netflix upgraded to Overweight from Equal Weight at Wells Fargo
- 11/30/22 Societe Generale
- Netflix price target raised to $215 from $170 at Societe Generale
- 12/09/22 Mizuho
- Coinbase downgraded to Underperform from Neutral at Mizuho
- 12/05/22 Atlantic Equities
- Coinbase price target lowered to $46 from $67 at Atlantic Equities
- 12/02/22 Piper Sandler
- Piper calls for 'more aggressive headcount reduction' at Coinbase
- 11/22/22 Needham
- Coinbase price target lowered to $73 from $89 at Needham
- 12/09/22 Argus
- Beyond Meat downgraded to Sell at Argus on declining demand, competition
- 11/28/22 Barclays
- Beyond Meat downgraded to Underweight from Equal Weight at Barclays
- 11/23/22 Goldman Sachs
- Beyond Meat price target lowered to $5 from $14 at Goldman Sachs
- 11/10/22 Bernstein
- Beyond Meat price target lowered to $10 from $22 at Bernstein
JAZZ Jazz Pharmaceuticals - $151.94 /
+1.715 (+1.14%) - 12/08/22 Goldman Sachs
- Jazz Pharmaceuticals upgraded to Buy from Neutral at Goldman Sachs
- 11/30/22 Jefferies
- Avadel upgraded to Buy at Jefferies after survey of sleep doctors
- 11/21/22 Needham
- Avadel Pharmaceuticals price target raised to $9 from $8 at Needham
- 11/01/22 H.C. Wainwright
- H.C. Wainwright downgrades Zymeworks on Jazz opt-out possibility
- 12/09/22 Deutsche Bank
- Manchester United downgraded to Hold from Buy at Deutsche Bank
- 11/23/22 Jefferies
- Jefferies expects 'competitive process' for Manchester United
- 06/02/22 Deutsche Bank
- Manchester United undervalued after selloff, says Deutsche Bank
- 03/21/22 Deutsche Bank
- Manchester United upgraded on 'value disconnect' at Deutsche Bank
- 11/18/22 Wedbush
- GM's Investor Day event 'impressive,' says Wedbush
- 11/10/22 Wolfe Research
- General Motors downgraded to Peer Perform from Outperform at Wolfe Research
- 10/26/22 Deutsche Bank
- General Motors price target lowered to $35 from $36 at Deutsche Bank
- 10/26/22 JPMorgan
- General Motors price target raised to $59 from $58 at JPMorgan
- 08/11/22 Gordon Haskett
- New York Times share buys at UBS flagged by Gordon Haskett on activist link
- 08/04/22 Morgan Stanley
- New York Times price target lowered to $37 from $40 at Morgan Stanley
- 07/21/22 Guggenheim
- New York Times price target lowered to $34 from $41 at Guggenheim
- 06/22/22 Cannonball Research
- 'Not right market for' NYT story, Cannonball Research says in downgrade
- 12/08/22 Piper Sandler
- Piper says Shanghai Gigafactory rumors 'easier to understand' amid weak November
- 12/07/22 Bernstein
- Tesla may need to take additional price cuts in 2023, says Bernstein
- 12/05/22 Piper Sandler
- If Tesla cuts production in China, it won't be due to competition, says Piper
- 11/29/22 Bernstein
- Tesla risk/reward 'more balanced' after 48% drop, says Bernstein
- 12/06/22 Bernstein
- Walmart initiated with a Market Perform at Bernstein
- 12/01/22 Atlantic Equities
- Walmart price target raised to $165 from $150 at Atlantic Equities
- 11/18/22 Gordon Haskett
- Ross Stores upgraded to Buy at Gordon Haskett as off-price starts to turn corner
- 11/17/22 Truist
- Target price target lowered to $151 from $165 at Truist
- 11/15/22 Mizuho
- VMware price target lowered to $135 from $138 at Mizuho
- 10/17/22 Needham
- Nutanix price target raised to $31 from $25 at Needham
- 10/17/22 Northland
- Salesforce initiated with a Market Perform at Northland
- 07/06/22 Raymond James
- VMware downgraded to Market Perform from Outperform at Raymond James
- 12/09/22 Piper Sandler
- Gilead price target raised to $104 from $96 at Piper Sandler
- 10/31/22 Guggenheim
- Arcellx initiated with a Buy at Guggenheim
- 10/27/22 Needham
- Arcellx initiated with a Buy at Needham
- 07/20/22 Canaccord
- Canaccord starts Arcellx at Buy, sees 'best-in-class' potential
- 12/09/22 Morgan Stanley
- Vale upgraded to Overweight from Equal Weight at Morgan Stanley
- 12/08/22 BMO Capital
- Vale price target raised to $20 from $16 at BMO Capital
- 11/23/22 Deutsche Bank
- Vale upgraded to Buy from Hold at Deutsche Bank
- 10/05/22 Deutsche Bank
- Vale price target lowered to $19 from $20 at Deutsche Bank
- 01/03/22 Guggenheim
- Erasca price target lowered to $20 from $25 at Guggenheim
- $21.10 /
-2.995 (-12.43%) - 11/28/22 Jefferies
- Li Auto initiated with a Buy at Jefferies
- 11/25/22 DBS Bank
- Li Auto initiated with a Buy at DBS Bank
- 10/28/22 Barclays
- Li Auto price target lowered to $25 from $40 at Barclays
- 09/06/22 Morgan Stanley
- September 'crunch time' for China EV makers, says Morgan Stanley
- 08/31/22 Susquehanna
- Susquehanna downgrades Paysafe after CFO change, prefers to 'wait and see'
- 08/31/22 Susquehanna
- Paysafe downgraded to Neutral from Positive at Susquehanna
- 08/11/22 Credit Suisse
- Paysafe downgraded to Underperform from Neutral at Credit Suisse
- 08/10/22 RBC Capital
- Paysafe downgraded to Sector Perform from Outperform at RBC Capital
- 12/09/22 Baird
- Chewy price target raised to $50 from $45 at Baird
- 12/09/22 Barclays
- Chewy price target raised to $35 from $30 at Barclays
- 12/07/22 Wolfe Research
- Chewy downgraded to Peer Perform from Outperform at Wolfe Research
- 11/28/22 Wedbush
- Black Friday winners Include Best Buy, losers include Pets, says Wedbush
- $483.08 /
+1.755 (+0.36%) - 12/09/22 Truist
- Costco price target lowered to $538 from $557 at Truist
- 12/09/22 MKM Partners
- Costco price target lowered to $484 from $512 at MKM Partners
- 12/09/22 BMO Capital
- Costco price target lowered to $555 from $600 at BMO Capital
- 12/09/22 Loop Capital
- Costco price target lowered to $545 from $565 at Loop Capital
- 09/12/22 UBS
- National Beverage price target lowered to $42 from $43 at UBS
- $309.44 /
-10.41 (-3.25%) - 12/09/22 Baird
- Cooper Companies price target lowered to $355 from $370 at Baird
- 12/09/22 Piper Sandler
- Cooper Companies price target lowered to $350 from $355 at Piper Sandler
- 11/30/22 Baird
- Cooper Companies upgraded to Outperform from Neutral at Baird
- 11/28/22 JPMorgan
- Cooper Companies price target raised to $330 from $300 at JPMorgan
- 10/04/22 Northland
- Comtech cloud messaging customer likely AT&T or T-Mobile, says Northland
- 06/15/22 Jefferies
- Comtech downgraded to Hold from Buy at Jefferies
- 06/13/22 Noble Capital
- Comtech upgraded to Outperform from Market Perform at Noble Capital
- 06/10/22 Citi
- Comtech price target lowered to $14 from $20 at Citi
- 11/15/22
- Walmart raises FY23 adjusted EPS view to down 5%-6% from down 9%-11%
- 11/15/22
- Walmart raises FY23 adjusted EPS view to down 6%-7% from down 9%-11%
- 11/15/22
- Walmart sees Q4 adjusted EPS down 3%-5%, consensus $1.46
- 11/15/22
- Walmart reports Q3 adjusted EPS $1.50, consensus $1.32
- 11/22/22
- VMware reports Q3 adjusted EPS $1.47, consensus $1.58
- 08/25/22
- VMware reports Q2 adjusted EPS $1.64 vs $1.75 last year
- 08/25/22
- Notable companies reporting after market close
- 10/19/22
- Tesla reports Q3 EPS $1.05, consensus 99c
- 10/19/22
- Notable companies reporting after market close
- 07/20/22
- Tesla reports Q2 EPS $2.27, consensus $1.85
- 07/20/22
- Notable companies reporting after market close
- 12/08/22
- RH narrow FY22 revenue growth view to down 4.5% to down 3.5%
- 12/08/22
- RH reports Q3 EPS $5.67, consensus $4.70
- 09/08/22
- RH sees Q3 revenue down 18% to down 15%
- 11/10/22
- Paysafe sees Q4 revenue $370M-$378M, consensus $370.81M
- 11/10/22
- Paysafe raises FY22 revenue view to $1.48B-$1.49B from $1.47B-$1.49B
- 11/10/22
- Paysafe reports Q3 EPS 0c, consensus 0c
- 11/02/22
- New York Times reports Q3 adjusted EPS 21c, consensus 13c
- 08/03/22
- New York Times reports Q2 adjusted EPS 24c, consensus 19c
- 10/18/22
- Netflix sees Q4 EPS 36c, consensus $1.12
- 10/18/22
- Netflix reports Q3 EPS $3.10, consensus $2.13
- 10/18/22
- Notable companies reporting after market close
- 07/19/22
- Netflix sees Q3 EPS $2.14, consensus $2.77
- 12/08/22
- Manchester United reports Q2 adjusted EBITDA GBP 23.6M vs. GBP 11.2M y/y
- 09/22/22
- Manchester United sees FY23 revenue GBP 580M-GBP 600M
- 09/22/22
- Manchester United reports Q4 adjusted EPS (GBP 12.38) vs. (GBP 20.67) last year
- $326.63 /
-48.88 (-13.02%) - 12/08/22
- Lululemon sees FY22 EPS $9.87-$9.97, consensus $9.92
- 12/08/22
- Lululemon sees Q4 EPS $4.20-$4.30, consensus $4.30
- 12/08/22
- Lululemon reports Q3 EPS $2.00, consensus $1.97
- $21.10 /
-2.995 (-12.43%) - 12/09/22
- Li Auto sees Q4 revenue $2.32B-$2.47B, consensus $2.55B
- 12/09/22
- Li Auto reports Q3 EPS (18c), consensus (15c)
- 08/15/22
- Li Auto sees Q3 revenue $1.34B-$1.43B, consensus $2.02B.
- 08/15/22
- Li Auto reports Q2 EPS (5c), consensus (6c)
JAZZ Jazz Pharmaceuticals - $151.94 /
+1.715 (+1.14%) - 11/09/22
- Jazz Pharmaceuticals raises FY22 EPS view to $17.20-$17.85 from $16.70-$17.70
- 11/09/22
- Jazz Pharmaceuticals reports Q3 adjusted EPS $5.17, consensus $4.66
- 08/03/22
- Jazz Pharmaceuticals backs FY22 revenue view $3.5B-$3.7B, consensus $3.6B
- 08/03/22
- Jazz Pharmaceuticals backs FY22 non-GAAP EPS view $16.70-$17.70
- 11/17/22
- General Motors narrows FY22 EBIT-adjusted view to $13.5B-$14.5B from $13B-$15B
- 10/25/22
- General Motors backs FY22 adjusted EPS view $6.50-$7.50, consensus $6.79
- 10/25/22
- General Motors reports Q3 adjusted EPS $2.25, consensus $1.88
- 10/24/22
- Notable companies reporting before tomorrow's open
- 12/08/22
- National Beverage reports Q2 EPS 39c, two estimates 34c
- 06/29/22
- National Beverage reports FY22 EPS $1.69, consensus $1.75
- 10/20/22
- Ericsson reports Q3 EPS SEK 1.56 vs. SEK 1.73 last year
- 07/14/22
- Ericsson reports Q1 EPS SEK 1.35 vs. SEK 1.10 last year
- 11/09/22
- Erasca reports Q3 EPS (29c), consensus (31c)
- 12/08/22
- DocuSign sees FY23 revenue $2.493B-$2.497B, consensus $2.49B
- 12/08/22
- DocuSign sees Q4 revenue $637M-$641M, consensus $640.51M
- 12/08/22
- DocuSign reports Q3 adjusted EPS 57c, consensus 42c
- 12/08/22
- Notable companies reporting after market close
- $483.08 /
+1.755 (+0.36%) - 12/08/22
- Costco reports Q1 EPS $3.07, consensus $3.11
- 11/30/22
- Costco Reports Q1 revenue $53.44B, consensus $54.9B
- 09/22/22
- Costco reports Q4 total revenue $72.1M, consensus $72.04B.
- $309.44 /
-10.41 (-3.25%) - 12/08/22
- Cooper Companies sees FY23 EPS $12.30 - $12.60, consensus $13.05
- 12/08/22
- Cooper Companies reports Q4 EPS $2.75, consensus $3.11
- 08/31/22
- Cooper Companies sees Q4 revenue $830M - $850M, consensus $841.43M
- 08/31/22
- Cooper Companies sees Q EPS12.72 - $12.87 , consensus $13.14
- 12/07/22
- Coinbase CEO tells Bloomberg 2022 revenue seen down 50% or more
- 11/03/22
- Coinbase reports Q3 EPS ($2.43), consensus ($2.40)
- 11/03/22
- Notable companies reporting after market close
- 08/09/22
- Coinbase reports Q2 EPS ($4.98), consensus ($2.65)
- 12/08/22
- Comtech sees Q2 revenue growth 1%-3% sequentially, consensus $128.1M
- 12/08/22
- Comtech reports Q1 EPS (46c), consensus (10c)
- 09/29/22
- Comtech sees Q1 revenue up 1%-3% sequentially
- 09/29/22
- Comtech reports Q4 EPS (2c), consensus (10c)
- 12/08/22
- Chewy raises FY22 revenue view to $10.02B-$10.04B from $9.9B-$10B
- 12/08/22
- Chewy sees Q4 revenue $2.63B-$2.65B, consensus $2.64B
- 12/08/22
- Chewy reports Q3 revenue $2.53B, consensus $2.46B
- 11/09/22
- Beyond Meat cuts FY22 revenue view to $400M-$425M from $470M-$520M
- 11/09/22
- Beyond Meat reports Q3 EPS ($1.60), consensus ($1.14)
- 11/09/22
- Notable companies reporting after market close
- 10/14/22
- Beyond Meat sees Q3 revenue $82M, consensus $117.11M
- $544.94 /
+14.235 (+2.68%) - 12/08/22
- Broadcom sees Q1 revenue $8.9B, consensus $8.79B
- 12/08/22
- Broadcom reports Q4 EPS $10.45, consensus $10.28
- 09/01/22
- Broadcom sees Q4 revenue $8.9B, consensus $8.73B
- 11/14/22
- Arcellx reports Q3 EPS ($2.12), consensus (89c)
- 08/15/22
- Arcellx reports Q2 EPS (88c), consensus ($1.07)
- 10/27/22
- Apple reports Q4 EPS $1.29, consensus $1.17
- 10/27/22
- Notable companies reporting after market close
- 07/28/22
- Apple reports Q3 EPS $1.20, consensus $1.16
- 07/28/22
- Notable companies reporting after market close
|
On The Fly
|
Get caught up quickly on… ShowHide Related Items >><< - 12/06/22
- Walmart to pay $500,000 over workers' compensation prescription procedures
- 12/01/22
- Digimarc expands partnership with Walmart
- 11/29/22
- Upexi's toy brand Tytan Tiles to launch in Walmart retail stores in January
- 11/23/22
- Walmart 'shocked' at 'tragic' event at Chesapeake, Virginia store
- 11/17/22
- General Motors, Vale sign long-term nickel supply agreement
- 08/15/22
- Vale fined BRL86.3M in Brazil over Brumadinho dam disclosures
- 07/28/22
- Vale reports Q2 iron ore production up 17% to 74.1 Mt
- 07/19/22
- Vale updates FY22 iron ore and copper production estimates
- 12/02/22
- Ford reports November U.S. sales down 7.8% to 146,364 vehicles
- 11/28/22
- Musk says Apple 'threatened to withhold Twitter' from App Store
- 12/08/22
- RH says Q3 gross margin contracted 50bps
- 12/08/22
- RH to acquire Dmitriy & Co
- 12/08/22
- RH CEO to exercise expiring options
- 11/14/22
- Berkshire Hathaway adds TSMC, exits STORE Capital in Q3
- 12/08/22
- Paysafe announces reverse stock split
- 11/29/22
- Paysafe enters new partnership with Virgin Voyages
- 11/15/22
- Paysafe launches paysafecard as alternative payment on Microsoft.com, Xbox.com
- 10/19/22
- Paysafe announces new integrated payments partnership with HotelKey
- 11/02/22
- New York Times sees Q4 subscription revenues up 17%-20%
- 08/11/22
- New York Times jumps after ValueAct discloses 6.7% active stake
- 08/03/22
- New York Times sees FY22 CapEx approximately $55M
- 07/14/22
- Hasbro, New York Times to launch new Wordle board game
- $327.92 /
+17.495 (+5.64%) - 12/06/22
- Netflix CEO Sarandos sees multiple ad tiers over time
- 12/01/22
- Enthusiast Gaming, Netflix enter content partnership for Geeked: Toon-in
- 11/14/22
- Appaloosa exits positions in Kohl's, Occidental Petroleum, Micron
- 11/07/22
- Netflix to adapt video game 'Gears of War' into feature film, animated series
- $327.38 /
-48.13 (-12.82%) - 12/08/22
- Lululemon falls 9% to $340.75 after Q3 results and guidance
- 12/08/22
- Lululemon reports Q3 SSS up 22% or 25% on constant FX basis
- 10/05/22
- Xponential Fitness debuts workouts on Lululemon Studio
- 09/30/22
- Peloton, Lululemon reach settlement over athletic wear
- 12/01/22
- Li Auto delivers 15,034 vehicles in November, up 11.5%
- 11/01/22
- Li Auto delivers 10,052 vehicles in October, up 31.4%
- 10/01/22
- Li Auto delivers 11,531 vehicles in September, up 62.5% year-over-year
JAZZ Jazz Pharmaceuticals - 11/29/22
- Zymeworks says Hart-Scott-Rodino wait expires for Zanidatamab deal with Jazz
- 11/28/22
- Jazz to present six presentations on advancements in epilepsy outcomes
- 11/18/22
- Avadel says Delaware Court ordered Jazz to delist REMS Patent from Orange Book
- 11/18/22
- Jazz announces FDA approval of sBLA for Rylaze dosing schedule
- 12/05/22
- Kore Group forms go to market alliance with Google Cloud
- 12/07/22
- Alphabet, Oracle, Amazon and Microsoft all awarded on $9B DoD cloud contract
- 12/06/22
- Google makes it easier to 'dive deeper, explore topics' related to a Search
- 12/06/22
- Google brings continuous scrolling to desktop Search
- 12/06/22
- Vietnam-based EV maker VinFast plans for U.S. IPO
- 12/09/22
- Mullen Automotive hires Dixon as General Manager of Government Sales
- 12/07/22
- Interest rates, slow economy weigh on U.S. auto dealers, Cox Automotive says
- 12/05/22
- GM's BrightDrop adds DHL Express Canada to customer portfolio
- 11/21/22
- Domino's Pizza to roll out nationwide fleet of 800 Chevy Bolt EVs
- 12/09/22
- Gilead subsidiary enters CART-ddBCMA commercialization agreement, sees dilution
- 12/09/22
- ImmunoGen announces clinical collaboration with Gilead Sciences
- 12/07/22
- Gilead's Kite Pharma, Daiichi Sankyo announce partnership revision
- 12/07/22
- Aeris to acquire IoT business from Ericsson, terms not disclosed
- 12/07/22
- Ericsson, Aeris sign pact for Accelerator and Connected Vehicle Cloud businesses
- 11/03/22
- Ericsson's Vonage to pay customers $100M in FTC court order
- 12/09/22
- Erasca announces pricing of underwritten offering of common stock
- 12/09/22
- Erasca, Novartis enter worldwide license agreement for naporafenib
- 11/30/22
- Erasca announces CTCSA with Pierre Fabre to evaluate ERAS-007
- 10/20/22
- Erasca announces CTCSA with Pfizer to evaluate ERAS-007
- 12/08/22
- DocuSign jumps 14% to $49.80 after Q3 results beat estimates
- 12/08/22
- DocuSign reports Q3 adjusted gross margin 83% vs. 82% last year
- 10/04/22
- Cathie Wood says moved out of DocuSign, did not understand competition
- 09/28/22
- DocuSign announces restructuring plan, to reduce workforce by 9%
- 12/09/22
- Carvana falls -9.5%
- 12/08/22
- Carvana rises 15.7%
- 12/08/22
- Carvana rises 8.0%
- 12/07/22
- Carvana falls -36.1%
- 11/30/22
- Costco November total SSS ex gas and FX rose 5.3%
- 11/30/22
- Costco reports November revenue $19.17B, Q1 SSS up 6.6%
- 11/15/22
- Large retailers, discount stores, Amazon jump on Q3 earnings beat by Walmart
- 11/02/22
- Costco reports October comparable sales up 6.0%
- 08/09/22
- Cooper Companies appoints Nicholas Khadder general counsel
- 12/02/22
- Coinbase says Apple blocked last app release on NFTs
- 11/30/22
- Coinbase Wallet to stop supporting BCH, ETC, XLM, XRP
- 11/21/22
- Crypto names down in pre-market as bitcoin falls to one-week low
- 11/16/22
- Cathie Wood's ARK Investment bought 245.6K shares of Coinbase today
- 10/27/22
- Comtech awarded over $50M of incremental funding by U.S. Military
- 10/03/22
- Comtech awarded a contract by Tier-1 MNO for over $30M+
- 09/21/22
- Comtech awarded FMS contract for Ukrainian Government, no terms
- 09/15/22
- Comtech awarded London Police Service next generation 9-1-1 contract
- 12/08/22
- Chewy says now expects FY22 capex to come in slightly below 2.5% of sales
- 10/20/22
- Chewy expands CarePlus with new plan by Lemonade Pet
- 08/31/22
- Chewy falls -7.3%
- 08/30/22
- Chewy sees FY22 adjusted EBITDA margin 1.75%-2%
- 11/14/22
- Beyond Meat and American Cancer Society sign multi-year research agreement
- 11/09/22
- Beyond Meat sees Q4 operating expenses mid-$60M range
- 11/07/22
- Beyond Meat expands chicken portfolio with Chicken Nuggets, Popcorn Chicken
- 10/24/22
- Beyond Meat debuts Beyond Steak
- $549.90 /
+19.195 (+3.62%) - 12/08/22
- Broadcom reports Q4 cash from operations $4.583B, free cash flow $4.461M
- 12/08/22
- Broadcom raises quarterly dividend 12% to $4.60 per share
- 10/25/22
- Broadcom's Rally Software receives FedRAMP authorization
- 10/18/22
- Broadcom showcases hyperscale solutions at 2022 OCP Global Summit
- 12/09/22
- Arcellx trading resumes
- 12/09/22
- Arcellx reports results from CART-ddBCMA Phase 1 expansion trial
- 12/09/22
- Arcellx, Kite collaborate to develop CART-ddBCMA
- 12/09/22
- Arcellx trading halted, news pending
- 12/09/22
- Apple says employees have 'right to speak freely' about workplace conditions
- 12/09/22
- Apple, Ericsson sign global patent license agreement
- 12/07/22
- Apple introduces three new advanced data security features
- 12/06/22
- Apple updates App Store pricing, offers 700 new price points
- $327.92 /
+17.495 (+5.64%) - 12/09/22 Cowen
- Netflix price target raised to $405 at Cowen, named a 'Best Idea for 2023'
- 12/09/22 Wells Fargo
- Wells Fargo upgrades Netflix shares on 'more ways to win' in 2023
- 12/09/22 Wells Fargo
- Netflix upgraded to Overweight from Equal Weight at Wells Fargo
- 11/30/22 Societe Generale
- Netflix price target raised to $215 from $170 at Societe Generale
- 12/09/22 Mizuho
- Coinbase downgraded to Underperform from Neutral at Mizuho
- 12/05/22 Atlantic Equities
- Coinbase price target lowered to $46 from $67 at Atlantic Equities
- 12/02/22 Piper Sandler
- Piper calls for 'more aggressive headcount reduction' at Coinbase
- 11/22/22 Needham
- Coinbase price target lowered to $73 from $89 at Needham
- 12/09/22 Argus
- Beyond Meat downgraded to Sell at Argus on declining demand, competition
- 11/28/22 Barclays
- Beyond Meat downgraded to Underweight from Equal Weight at Barclays
- 11/23/22 Goldman Sachs
- Beyond Meat price target lowered to $5 from $14 at Goldman Sachs
- 11/10/22 Bernstein
- Beyond Meat price target lowered to $10 from $22 at Bernstein
JAZZ Jazz Pharmaceuticals - 12/08/22 Goldman Sachs
- Jazz Pharmaceuticals upgraded to Buy from Neutral at Goldman Sachs
- 11/30/22 Jefferies
- Avadel upgraded to Buy at Jefferies after survey of sleep doctors
- 11/21/22 Needham
- Avadel Pharmaceuticals price target raised to $9 from $8 at Needham
- 11/01/22 H.C. Wainwright
- H.C. Wainwright downgrades Zymeworks on Jazz opt-out possibility
- 12/09/22 Jefferies
- Vroom price target lowered to $1.10 from $1.30 at Jefferies
- 12/09/22 Jefferies
- Carvana price target lowered to $5 from $10 at Jefferies
- 12/09/22 Needham
- Needham downgrades Carvana, struggles to see near-term path forward
- 12/09/22 Needham
- Carvana downgraded to Hold from Buy at Needham
- 12/09/22 BofA
- DocuSign price target lowered to $65 from $80 at BofA
- 12/09/22 Piper Sandler
- DocuSign upgraded to Neutral from Underweight at Piper Sandler
- 12/06/22 Citi
- DocuSign price target lowered to $59 from $76 at Citi
- 12/05/22 UBS
- DocuSign price target lowered to $52 from $65 at UBS
- $549.90 /
+19.195 (+3.62%) - 12/09/22 Truist
- Broadcom price target raised to $662 from $630 at Truist
- 12/09/22 BofA
- Broadcom price target raised to $650 from $625 at BofA
- 12/09/22 Wells Fargo
- Broadcom resumed with an Equal Weight at Wells Fargo
- 12/09/22 Cowen
- Broadcom price target raised to $555 from $540 at Cowen
- $327.38 /
-48.13 (-12.82%) - 12/09/22 Morgan Stanley
- Lululemon price target raised to $387 from $343 at Morgan Stanley
- 12/09/22 Jefferies
- Jefferies says 'sell shares now' with Lululemon Q3 'as good as it gets'
- 12/09/22 Wells Fargo
- Lululemon price target raised to $360 from $345 at Wells Fargo
- 12/09/22 Goldman Sachs
- Lululemon removed from Conviction Buy list at Goldman on tough comps
- 12/07/22 Morgan Stanley
- Morgan Stanley 'incrementally more conservative' on Apple's December quarter
- 12/06/22 UBS
- Apple iPhone 14 Pro/Pro Max delivery times finally easing, says UBS
- 12/05/22 Wedbush
- Apple shift out of China will not be easy, says Wedbush
- 12/02/22 Morgan Stanley
- Morgan Stanley sees December quarter App Store forecast as 'conservative'
- 12/08/22 Societe Generale
- Ericsson price target raised to SEK 64 from SEK 55 at Societe Generale
- 11/09/22 Deutsche Bank
- Ericsson price target lowered to SEK 70 from SEK 80 at Deutsche Bank
- 11/08/22 Morgan Stanley
- Ericsson initiated with an Equal Weight at Morgan Stanley
- 11/01/22 JPMorgan
- Ericsson price target lowered to SEK 101 from SEK 125 at JPMorgan
- 12/09/22 Morgan Stanley
- RH price target lowered to $300 from $325 at Morgan Stanley
- 12/09/22 Jefferies
- RH price target lowered to $322 from $375 at Jefferies
- 12/09/22 Baird
- RH price target raised to $300 from $275 at Baird
- 11/21/22 Barclays
- RH downgraded to Equal Weight from Overweight at Barclays
- 11/18/22 Wedbush
- GM's Investor Day event 'impressive,' says Wedbush
- 11/10/22 Wolfe Research
- General Motors downgraded to Peer Perform from Outperform at Wolfe Research
- 10/26/22 Deutsche Bank
- General Motors price target lowered to $35 from $36 at Deutsche Bank
- 10/26/22 JPMorgan
- General Motors price target raised to $59 from $58 at JPMorgan
- 12/08/22 Citi
- DoD contracts shows competitiveness of cloud industry, says Citi
- 11/30/22 Societe Generale
- Alphabet price target lowered to $132 from $147 at Societe Generale
- 11/29/22 Lake Street
- Google Health partnership 'significant positive' for iCAD, says Lake Street
- 11/15/22 Morgan Stanley
- Alphabet price target lowered to $120 from $125 at Morgan Stanley
- 11/30/22 Mizuho
- Alphabet price target lowered to $135 from $140 at Mizuho
- 11/23/22 JMP Securities
- Alphabet price target lowered to $132 from $145 at JMP Securities
- 08/11/22 Gordon Haskett
- New York Times share buys at UBS flagged by Gordon Haskett on activist link
- 08/04/22 Morgan Stanley
- New York Times price target lowered to $37 from $40 at Morgan Stanley
- 07/21/22 Guggenheim
- New York Times price target lowered to $34 from $41 at Guggenheim
- 06/22/22 Cannonball Research
- 'Not right market for' NYT story, Cannonball Research says in downgrade
- 12/08/22 Piper Sandler
- Piper says Shanghai Gigafactory rumors 'easier to understand' amid weak November
- 12/07/22 Bernstein
- Tesla may need to take additional price cuts in 2023, says Bernstein
- 12/05/22 Piper Sandler
- If Tesla cuts production in China, it won't be due to competition, says Piper
- 11/29/22 Bernstein
- Tesla risk/reward 'more balanced' after 48% drop, says Bernstein
- 12/06/22 Bernstein
- Walmart initiated with a Market Perform at Bernstein
- 12/01/22 Atlantic Equities
- Walmart price target raised to $165 from $150 at Atlantic Equities
- 11/18/22 Gordon Haskett
- Ross Stores upgraded to Buy at Gordon Haskett as off-price starts to turn corner
- 11/17/22 Truist
- Target price target lowered to $151 from $165 at Truist
- 12/09/22 Baird
- Chewy price target raised to $50 from $45 at Baird
- 12/09/22 Barclays
- Chewy price target raised to $35 from $30 at Barclays
- 12/07/22 Wolfe Research
- Chewy downgraded to Peer Perform from Outperform at Wolfe Research
- 11/28/22 Wedbush
- Black Friday winners Include Best Buy, losers include Pets, says Wedbush
- 12/09/22 Truist
- Costco price target lowered to $538 from $557 at Truist
- 12/09/22 MKM Partners
- Costco price target lowered to $484 from $512 at MKM Partners
- 12/09/22 BMO Capital
- Costco price target lowered to $555 from $600 at BMO Capital
- 12/09/22 Loop Capital
- Costco price target lowered to $545 from $565 at Loop Capital
- 09/12/22 UBS
- National Beverage price target lowered to $42 from $43 at UBS
- 12/09/22 Baird
- Cooper Companies price target lowered to $355 from $370 at Baird
- 12/09/22 Piper Sandler
- Cooper Companies price target lowered to $350 from $355 at Piper Sandler
- 11/30/22 Baird
- Cooper Companies upgraded to Outperform from Neutral at Baird
- 11/28/22 JPMorgan
- Cooper Companies price target raised to $330 from $300 at JPMorgan
- 10/31/22 Guggenheim
- Arcellx initiated with a Buy at Guggenheim
- 10/27/22 Needham
- Arcellx initiated with a Buy at Needham
- 07/20/22 Canaccord
- Canaccord starts Arcellx at Buy, sees 'best-in-class' potential
- 07/20/22 Canaccord
- Arcellx initiated with a Buy at Canaccord
- 12/09/22 DZ Bank
- Gilead downgraded to Hold from Buy at DZ Bank
- 12/08/22 Piper Sandler
- Daiichi data competitive to Trodelvy, but 2 years behind Gilead, says Piper
- 12/05/22 RBC Capital
- Gilead discontinuation 'curious,' but shouldn't derail cancer momentum, says RBC
- 12/01/22 Oppenheimer
- Gilead price target raised to $105 from $95 at Oppenheimer
- 12/09/22 Morgan Stanley
- Vale upgraded to Overweight from Equal Weight at Morgan Stanley
- 12/08/22 BMO Capital
- Vale price target raised to $20 from $16 at BMO Capital
- 11/23/22 Deutsche Bank
- Vale upgraded to Buy from Hold at Deutsche Bank
- 10/05/22 Deutsche Bank
- Vale price target lowered to $19 from $20 at Deutsche Bank
- 01/03/22 Guggenheim
- Erasca price target lowered to $20 from $25 at Guggenheim
- 11/28/22 Jefferies
- Li Auto initiated with a Buy at Jefferies
- 11/25/22 DBS Bank
- Li Auto initiated with a Buy at DBS Bank
- 10/28/22 Barclays
- Li Auto price target lowered to $25 from $40 at Barclays
- 09/06/22 Morgan Stanley
- September 'crunch time' for China EV makers, says Morgan Stanley
- 08/31/22 Susquehanna
- Susquehanna downgrades Paysafe after CFO change, prefers to 'wait and see'
- 08/31/22 Susquehanna
- Paysafe downgraded to Neutral from Positive at Susquehanna
- 08/11/22 Credit Suisse
- Paysafe downgraded to Underperform from Neutral at Credit Suisse
- 08/10/22 RBC Capital
- Paysafe downgraded to Sector Perform from Outperform at RBC Capital
- 10/04/22 Northland
- Comtech cloud messaging customer likely AT&T or T-Mobile, says Northland
- 06/15/22 Jefferies
- Comtech downgraded to Hold from Buy at Jefferies
- 06/13/22 Noble Capital
- Comtech upgraded to Outperform from Market Perform at Noble Capital
- 06/10/22 Citi
- Comtech price target lowered to $14 from $20 at Citi
- 11/15/22
- Walmart raises FY23 adjusted EPS view to down 5%-6% from down 9%-11%
- 11/15/22
- Walmart raises FY23 adjusted EPS view to down 6%-7% from down 9%-11%
- 11/15/22
- Walmart sees Q4 adjusted EPS down 3%-5%, consensus $1.46
- 11/15/22
- Walmart reports Q3 adjusted EPS $1.50, consensus $1.32
- 10/19/22
- Tesla reports Q3 EPS $1.05, consensus 99c
- 10/19/22
- Notable companies reporting after market close
- 07/20/22
- Tesla reports Q2 EPS $2.27, consensus $1.85
- 07/20/22
- Notable companies reporting after market close
- 12/08/22
- RH narrow FY22 revenue growth view to down 4.5% to down 3.5%
- 12/08/22
- RH reports Q3 EPS $5.67, consensus $4.70
- 09/08/22
- RH sees Q3 revenue down 18% to down 15%
- 11/10/22
- Paysafe sees Q4 revenue $370M-$378M, consensus $370.81M
- 11/10/22
- Paysafe raises FY22 revenue view to $1.48B-$1.49B from $1.47B-$1.49B
- 11/10/22
- Paysafe reports Q3 EPS 0c, consensus 0c
- 11/02/22
- New York Times reports Q3 adjusted EPS 21c, consensus 13c
- 08/03/22
- New York Times reports Q2 adjusted EPS 24c, consensus 19c
- $327.92 /
+17.495 (+5.64%) - 10/18/22
- Netflix sees Q4 EPS 36c, consensus $1.12
- 10/18/22
- Netflix reports Q3 EPS $3.10, consensus $2.13
- 10/18/22
- Notable companies reporting after market close
- 07/19/22
- Netflix sees Q3 EPS $2.14, consensus $2.77
- $327.38 /
-48.13 (-12.82%) - 12/08/22
- Lululemon sees FY22 EPS $9.87-$9.97, consensus $9.92
- 12/08/22
- Lululemon sees Q4 EPS $4.20-$4.30, consensus $4.30
- 12/08/22
- Lululemon reports Q3 EPS $2.00, consensus $1.97
- 12/09/22
- Li Auto sees Q4 revenue $2.32B-$2.47B, consensus $2.55B
- 12/09/22
- Li Auto reports Q3 EPS (18c), consensus (15c)
- 08/15/22
- Li Auto sees Q3 revenue $1.34B-$1.43B, consensus $2.02B.
- 08/15/22
- Li Auto reports Q2 EPS (5c), consensus (6c)
JAZZ Jazz Pharmaceuticals - 11/09/22
- Jazz Pharmaceuticals raises FY22 EPS view to $17.20-$17.85 from $16.70-$17.70
- 11/09/22
- Jazz Pharmaceuticals reports Q3 adjusted EPS $5.17, consensus $4.66
- 08/03/22
- Jazz Pharmaceuticals backs FY22 revenue view $3.5B-$3.7B, consensus $3.6B
- 08/03/22
- Jazz Pharmaceuticals backs FY22 non-GAAP EPS view $16.70-$17.70
- 10/25/22
- Alphabet reports Q3 EPS $1.06, consensus $1.25
- 10/25/22
- Notable companies reporting after market close
- 07/26/22
- Alphabet reports Q2 EPS $1.21, consensus $1.30
- 07/26/22
- Notable companies reporting after market close
- 11/17/22
- General Motors narrows FY22 EBIT-adjusted view to $13.5B-$14.5B from $13B-$15B
- 10/25/22
- General Motors backs FY22 adjusted EPS view $6.50-$7.50, consensus $6.79
- 10/25/22
- General Motors reports Q3 adjusted EPS $2.25, consensus $1.88
- 10/24/22
- Notable companies reporting before tomorrow's open
- 10/27/22
- Gilead raises FY22 adjusted EPS view to $6.95-$7.15 from $6.35-$6.75
- 10/27/22
- Gilead Sciences reports Q3 adjusted EPS $1.90, consensus $1.43
- 08/02/22
- Gilead raises FY22 adjusted EPS view $6.35-$6.75 from $6.20-$6.70
- 12/08/22
- National Beverage reports Q2 EPS 39c, two estimates 34c
- 06/29/22
- National Beverage reports FY22 EPS $1.69, consensus $1.75
- 10/20/22
- Ericsson reports Q3 EPS SEK 1.56 vs. SEK 1.73 last year
- 07/14/22
- Ericsson reports Q1 EPS SEK 1.35 vs. SEK 1.10 last year
- 11/09/22
- Erasca reports Q3 EPS (29c), consensus (31c)
- 12/08/22
- DocuSign sees FY23 revenue $2.493B-$2.497B, consensus $2.49B
- 12/08/22
- DocuSign sees Q4 revenue $637M-$641M, consensus $640.51M
- 12/08/22
- DocuSign reports Q3 adjusted EPS 57c, consensus 42c
- 12/08/22
- Notable companies reporting after market close
- 11/03/22
- Carvana sees sequential reduction in retail units sold in Q4
- 11/03/22
- Carvana reports Q3 EPS ($2.67), consensus ($1.94)
- 08/04/22
- Carvana reports Q2 EPS ($2.35), consensus ($1.79)
- 12/08/22
- Costco reports Q1 EPS $3.07, consensus $3.11
- 11/30/22
- Costco Reports Q1 revenue $53.44B, consensus $54.9B
- 09/22/22
- Costco reports Q4 total revenue $72.1M, consensus $72.04B.
- 12/08/22
- Cooper Companies sees FY23 EPS $12.30 - $12.60, consensus $13.05
- 12/08/22
- Cooper Companies reports Q4 EPS $2.75, consensus $3.11
- 08/31/22
- Cooper Companies sees Q4 revenue $830M - $850M, consensus $841.43M
- 08/31/22
- Cooper Companies sees Q EPS12.72 - $12.87 , consensus $13.14
- 12/07/22
- Coinbase CEO tells Bloomberg 2022 revenue seen down 50% or more
- 11/03/22
- Coinbase reports Q3 EPS ($2.43), consensus ($2.40)
- 11/03/22
- Notable companies reporting after market close
- 08/09/22
- Coinbase reports Q2 EPS ($4.98), consensus ($2.65)
- 12/08/22
- Comtech sees Q2 revenue growth 1%-3% sequentially, consensus $128.1M
- 12/08/22
- Comtech reports Q1 EPS (46c), consensus (10c)
- 09/29/22
- Comtech sees Q1 revenue up 1%-3% sequentially
- 09/29/22
- Comtech reports Q4 EPS (2c), consensus (10c)
- 12/08/22
- Chewy raises FY22 revenue view to $10.02B-$10.04B from $9.9B-$10B
- 12/08/22
- Chewy sees Q4 revenue $2.63B-$2.65B, consensus $2.64B
- 12/08/22
- Chewy reports Q3 revenue $2.53B, consensus $2.46B
- 11/09/22
- Beyond Meat cuts FY22 revenue view to $400M-$425M from $470M-$520M
- 11/09/22
- Beyond Meat reports Q3 EPS ($1.60), consensus ($1.14)
- 11/09/22
- Notable companies reporting after market close
- 10/14/22
- Beyond Meat sees Q3 revenue $82M, consensus $117.11M
- $549.90 /
+19.195 (+3.62%) - 12/08/22
- Broadcom sees Q1 revenue $8.9B, consensus $8.79B
- 12/08/22
- Broadcom reports Q4 EPS $10.45, consensus $10.28
- 09/01/22
- Broadcom sees Q4 revenue $8.9B, consensus $8.73B
- 11/14/22
- Arcellx reports Q3 EPS ($2.12), consensus (89c)
- 08/15/22
- Arcellx reports Q2 EPS (88c), consensus ($1.07)
- 10/27/22
- Apple reports Q4 EPS $1.29, consensus $1.17
- 10/27/22
- Notable companies reporting after market close
- 07/28/22
- Apple reports Q3 EPS $1.20, consensus $1.16
- 07/28/22
- Notable companies reporting after market close
|
Syndicate
|
JPMorgan and Goldman… JPMorgan and Goldman Sachs acted as joint book running managers for the offering. ShowHide Related Items >><< - 12/09/22
- Erasca announces pricing of underwritten offering of common stock
- 12/09/22
- Erasca, Novartis enter worldwide license agreement for naporafenib
- 11/30/22
- Erasca announces CTCSA with Pierre Fabre to evaluate ERAS-007
- 10/20/22
- Erasca announces CTCSA with Pfizer to evaluate ERAS-007
- 01/03/22 Guggenheim
- Erasca price target lowered to $20 from $25 at Guggenheim
- 11/09/22
- Erasca reports Q3 EPS (29c), consensus (31c)
|
Hot Stocks
|
Erasca announced the… Erasca announced the pricing of an underwritten offering of 15,384,616 shares of its common stock at a price of $6.50 per share. All of the shares to be sold in the offering are to be sold by Erasca. The gross proceeds to Erasca from the offering, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be approximately $100M. The offering is expected to close on December 13, 2022, subject to the satisfaction of customary closing conditions. Erasca intends to use the net proceeds from this offering, together with its existing cash, cash equivalents and marketable securities, to fund the research and development of its product candidates and other development programs and for working capital and other general corporate purposes. J.P. Morgan and Goldman Sachs & Co. LLC are acting as joint book-running managers for the offering. ShowHide Related Items >><< - 12/09/22
- Erasca, Novartis enter worldwide license agreement for naporafenib
- 11/30/22
- Erasca announces CTCSA with Pierre Fabre to evaluate ERAS-007
- 10/20/22
- Erasca announces CTCSA with Pfizer to evaluate ERAS-007
- 10/12/22
- Erasca announces four poster presentations at EORTC-NCI-AACR Symposium
- 01/03/22 Guggenheim
- Erasca price target lowered to $20 from $25 at Guggenheim
- 11/09/22
- Erasca reports Q3 EPS (29c), consensus (31c)
|
Hot Stocks
|
Erasca (ERAS) entered… Erasca (ERAS) entered into an exclusive worldwide license agreement with Novartis (NVS) for naporafenib, a Phase 2 pivotal-ready pan-RAF inhibitor with a potential profile in NRAS mutant melanoma and other RAS/MAPK pathway-driven tumors. To date, naporafenib has been dosed in over 500 patients across multiple trials and has demonstrated preliminary clinical proof-of-concept as well as favorable safety and tolerability data both as a single agent and in combination with other molecularly targeted and immuno-oncology therapies. As separately announced, Erasca has priced a $100M equity offering with select healthcare investors. Naporafenib is a potent and selective inhibitor of BRAF and CRAF. Safety, tolerability, and preliminary proof of concept of naporafenib alone or in combination have been shown in over 500 patients treated to date in NRASm melanoma and other RAS/MAPK pathway-driven tumors. Erasca plans to initially focus on advancing and securing potential regulatory approval for naporafenib plus trametinib in RAS Q61X tissue agnostic solid tumors as part of the planned Phase 2 SEACRAFT-1 trial and NRASm melanoma as part of the planned Phase 3 SEACRAFT-2 trial. Under the terms of the license agreement, in exchange for an exclusive worldwide license to develop and commercialize naporafenib, Erasca will pay to Novartis a one-time upfront cash payment of $20M and $80M of shares in Erasca common stock at a price of $6.50 per share. Novartis is eligible to receive up to $80M in cash upon the achievement of regulatory milestones covering two indications in the United States, Europe, and Japan, as well as up to $200M in cash upon the achievement of sales milestones. Novartis is also eligible to receive a low single-digit percentage royalty on net sales of naporafenib. ShowHide Related Items >><< - 12/08/22
- Novartis reports Phase 3 APPOINT-PNH study met primary endpoint
- 12/06/22
- Novartis announces results from RIGHT Choice Phase II trial of Kisqali
- 12/05/22
- Novartis reports Phase 3 PSMAfore trial with Pluvicto met primary endpoint
- 11/22/22
- Novartis to present data on breast cancer, hematology advancements at SBACS, ASH
- 11/30/22
- Erasca announces CTCSA with Pierre Fabre to evaluate ERAS-007
- 10/20/22
- Erasca announces CTCSA with Pfizer to evaluate ERAS-007
- 10/12/22
- Erasca announces four poster presentations at EORTC-NCI-AACR Symposium
- 09/07/22
- Erasca announces preliminary ERAS-007, ERAS-601 data
- 01/03/22 Guggenheim
- Erasca price target lowered to $20 from $25 at Guggenheim
- 12/05/22 Stifel
- Novartis upgraded to Buy from Hold at Stifel
- 10/26/22 JPMorgan
- Novartis price target lowered to CHF 78 from CHF 81 at JPMorgan
- 10/14/22 Barclays
- Novartis price target lowered to CHF 75 from CHF 85 at Barclays
- 10/07/22 Deutsche Bank
- Novartis price target lowered to CHF 70 from CHF 75 at Deutsche Bank
- 10/25/22
- Novartis confirms mid single digit sales, core operating income guidance
- 10/25/22
- Novartis reports Q3 core EPS $1.58 vs. $1.71 last year
- 09/22/22
- Novartis sees 4% sales CAGR through 2027
- 07/19/22
- Novartis reports Q2 core EPS $1.56 vs. $1.66 a year ago
- 11/09/22
- Erasca reports Q3 EPS (29c), consensus (31c)
- 11/16/22
- Novartis exploring sale of ophthalmology, respiratory units, Bloomberg says
- 10/20/22
- Drugmakers look to limit Medicare's power to negotiate drug prices, WSJ reports
- 10/13/22
- Novartis to cut up to 400 jobs from Dublin operations, RTE reports
- 09/29/22
- Novartis gets pause in Gilenya patent dispute, Bloomberg reports
- 09/15/22
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 09/07/22
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 08/25/22
- What You Missed On Wall Street On Thursday
- 08/25/22
- What You Missed On Wall Street This Morning
- 10/06/22
- Novartis put volume heavy and directionally bearish
- 08/09/22
- Largest borrow rate increases among liquid names
|
Hot Stocks
|
Erasca announced a… Erasca announced a clinical trial collaboration and supply agreement, CTCSA, with Pierre Fabre for the BRAF inhibitor encorafenib within key international territories. This agreement will support a clinical proof-of-concept trial evaluating ERAS-007, an oral ERK1/2 inhibitor, in combination with encorafenib and the anti-EGFR antibody cetuximab for the treatment of patients with BRAF V600E-mutant metastatic colorectal cancer. This combination is being investigated as part of the ongoing Phase 1b/2 HERKULES-3 master protocol in patients with gastrointestinal malignancies. Erasca will sponsor the trial, and Pierre Fabre will supply encorafenib in the Pierre Fabre territories which include Europe and Asia Pacific. "We are excited to work with Pierre Fabre, a leader in precision oncology, on an international collaboration to explore ERAS-007 in combination with encorafenib and cetuximab in BRAF mCRC," said Jonathan E. Lim, M.D., Erasca's chairman, CEO, and co-founder. "This partnership complements our existing CTCSA with Pfizer for encorafenib within the United States and other markets. Resistance mechanisms, particularly through MAPK reactivation, limit long-term benefit with current standard of care BRAF-targeted treatments. By blocking RAS/MAPK pathway signaling at the most distal node, ERK1/2, ERAS-007 can potentially prevent pathway reactivation." ShowHide Related Items >><< - 10/20/22
- Erasca announces CTCSA with Pfizer to evaluate ERAS-007
- 10/12/22
- Erasca announces four poster presentations at EORTC-NCI-AACR Symposium
- 09/07/22
- Erasca announces preliminary ERAS-007, ERAS-601 data
- 08/24/22
- Erasca to host R&D Day on ERAS-007, ERAS-601 in advanced solid tumors
- 01/03/22 Guggenheim
- Erasca price target lowered to $20 from $25 at Guggenheim
- 11/09/22
- Erasca reports Q3 EPS (29c), consensus (31c)
- 06/08/22
- Twelve new option listings and one option delisting on June 8th
|
Earnings
|
Cash, cash equivalents,… Cash, cash equivalents, and marketable securities were $365.5M as of September 30, 2022, compared to $459.2M as of December 31, 2021. Erasca expects its current cash, cash equivalents, and marketable securities balance to fund operations into the second half of 2024. ShowHide Related Items >><< - 10/20/22
- Erasca announces CTCSA with Pfizer to evaluate ERAS-007
- 10/12/22
- Erasca announces four poster presentations at EORTC-NCI-AACR Symposium
- 09/07/22
- Erasca announces preliminary ERAS-007, ERAS-601 data
- 08/24/22
- Erasca to host R&D Day on ERAS-007, ERAS-601 in advanced solid tumors
- 01/03/22 Guggenheim
- Erasca price target lowered to $20 from $25 at Guggenheim
- 05/12/22
- Erasca reports Q EPS (31c), consensus (29c)
- 06/08/22
- Twelve new option listings and one option delisting on June 8th
|